These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11790612)

  • 21. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
    Seidman AD; Hochhauser D; Gollub M; Edelman B; Yao TJ; Hudis CA; Francis P; Fennelly D; Gilewski TA; Moynahan ME; Currie V; Baselga J; Tong W; O'Donaghue M; Salvaggio R; Auguste L; Spriggs D; Norton L
    J Clin Oncol; 1996 Jun; 14(6):1877-84. PubMed ID: 8656256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Taxane containing regimens for metastatic breast cancer.
    Ghersi D; Wilcken N; Simes J; Donoghue E
    Cochrane Database Syst Rev; 2003; (3):CD003366. PubMed ID: 12917963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Neoadjuvant chemotherapy for breast-conservative surgery].
    Kusama M; Kaise H; Koyanagi Y
    Nihon Rinsho; 2000 Apr; 58 Suppl():215-22. PubMed ID: 11025998
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
    Kim ES; Kies MS; Fossella FV; Glisson BS; Zaknoen S; Statkevich P; Munden RF; Summey C; Pisters KM; Papadimitrakopoulou V; Tighiouart M; Rogatko A; Khuri FR
    Cancer; 2005 Aug; 104(3):561-9. PubMed ID: 16028213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
    Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of vinorelbine monotherapy in taxane-treated patients with advanced non-small-cell lung cancer.
    Miyata J; Sano T; Bando H
    Med Oncol; 2002; 19(1):11-4. PubMed ID: 12025886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy.
    Wosnitzer MS; Domingo-Domenech J; Castillo-Martin M; Ritch C; Mansukhani M; Petrylack DP; Benson MC; McKiernan JM; Cordon-Cardo C
    J Urol; 2011 Nov; 186(5):2094-100. PubMed ID: 21944130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival following the documentation of platinum and taxane resistance in ovarian cancer.
    Büyükçelik A; Yalçin B; Utkan G; Doruk H
    Gynecol Oncol; 2004 Dec; 95(3):774-5; author reply 775-6. PubMed ID: 15582006
    [No Abstract]   [Full Text] [Related]  

  • 29. Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan.
    Verschraegen CF; Levenback C; Vincent M; Wolf J; Bevers M; Loyer E; Kudelka AP; Kavanagh JJ
    Ann N Y Acad Sci; 2000; 922():349-51. PubMed ID: 11193920
    [No Abstract]   [Full Text] [Related]  

  • 30. Management of Hypersensitivity Reactions to Taxanes.
    Picard M
    Immunol Allergy Clin North Am; 2017 Nov; 37(4):679-693. PubMed ID: 28965634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy.
    Kurzeder C; Sauer G; Deissler H
    Curr Cancer Drug Targets; 2006 May; 6(3):207-27. PubMed ID: 16712458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New advances in taxane therapy: the next generation.
    Seidman AD
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-5-8. PubMed ID: 23570091
    [No Abstract]   [Full Text] [Related]  

  • 33. American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 1.
    Walker K; Kibble A; Shumoogam J
    IDrugs; 2007 Aug; 10(8):513-6. PubMed ID: 17665320
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of taxanes in the treatment of breast cancer.
    Capri G; Tarenzi E; Fulfaro F; Gianni L
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
    Estévez LG; Gradishar WJ
    Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming multidrug resistance in taxane chemotherapy.
    Geney R; Ungureanu lM; Li D; Ojima I
    Clin Chem Lab Med; 2002 Sep; 40(9):918-25. PubMed ID: 12435109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Taxane-induced arthralgia and myalgia: A literature review.
    Chiu N; Chiu L; Chow R; Lam H; Verma S; Pasetka M; Chow E; DeAngelis C
    J Oncol Pharm Pract; 2017 Jan; 23(1):56-67. PubMed ID: 26811404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel in early breast cancer: a viewpoint by David A. Cameron.
    Cameron DA
    Drugs; 2004; 64(16):1848-9. PubMed ID: 15301567
    [No Abstract]   [Full Text] [Related]  

  • 39. [Chemotherapy for breast cancer refractory to anthracycline, taxane or trastuzumab].
    Ito Y; Kobayashi K
    Gan To Kagaku Ryoho; 2009 May; 36(5):726-9. PubMed ID: 19461171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.
    Krens SD; McLeod HL; Hertz DL
    Pharmacogenomics; 2013 Apr; 14(5):555-74. PubMed ID: 23556452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.